Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds bacterium or component thereof or substance produced...
Reexamination Certificate
2006-05-16
2006-05-16
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds bacterium or component thereof or substance produced...
C424S164100, C424S142100, C424S130100, C530S350000, C530S387100
Reexamination Certificate
active
07045131
ABSTRACT:
A method and composition for the passive immunization of patients infected with or susceptible to infection fromStaphylococcusbacteria such asS. aureusandS. epidermidisinfection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selectedStaphylococcusadhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host. In either case, the donor plasma pool is preferably purified and concentrated prior to intravenous introduction into the patient, and the present invention is advantageous in that a patient can be immunized against a wide variety of potentially dangerous staphylococcal infections. Kits for identifying potential donor with high titers of the selected adhesins are also provided. The present invention thus provides methods and compositions which can be highly effective against infections associated withStaphylococcusbacteria.
REFERENCES:
patent: 4245039 (1981-01-01), Heimburger et al.
patent: 4312942 (1982-01-01), Blobel et al.
patent: 4318902 (1982-03-01), Stephan
patent: 4732757 (1988-03-01), Stolle et al.
patent: 4965068 (1990-10-01), Stephan et al.
patent: 5034515 (1991-07-01), Proctor
patent: 5055455 (1991-10-01), Pier
patent: 5292513 (1994-03-01), Gristina et al.
patent: 5496706 (1996-03-01), Kuusela et al.
patent: 5505945 (1996-04-01), Gristina et al.
patent: 5530102 (1996-06-01), Gristina et al.
patent: 5571511 (1996-11-01), Fischer
patent: 5585106 (1996-12-01), Gristina et al.
patent: 5591441 (1997-01-01), Gristina et al.
patent: 5648240 (1997-07-01), Hook et al.
patent: 5681565 (1997-10-01), Gristina et al.
patent: 5707627 (1998-01-01), Gristina et al.
patent: 5718899 (1998-02-01), Gristina et al.
patent: 5770208 (1998-06-01), Fattom et al.
patent: 5770234 (1998-06-01), Gristina et al.
patent: 5776712 (1998-07-01), Kuusela et al.
patent: 5817312 (1998-10-01), Gristina et al.
patent: 5955074 (1999-09-01), Fischer
patent: 5955078 (1999-09-01), Burnham et al.
patent: 5980910 (1999-11-01), Pier
patent: 6008341 (1999-12-01), Foster et al.
patent: 6077677 (2000-06-01), Hodgson et al.
patent: 6177084 (2001-01-01), Foster et al.
patent: 6221397 (2001-04-01), Russell-Jones et al.
patent: 6274144 (2001-08-01), Wang et al.
patent: 6288214 (2001-09-01), Hook et al.
patent: 6299879 (2001-10-01), Boden Wastfalt et al.
patent: 6685943 (2004-02-01), Hook et al.
patent: 6692739 (2004-02-01), Patti et al.
patent: 6733758 (2004-05-01), Guss et al.
patent: 2003/0006209 (2003-01-01), Stefen et al.
patent: 2003/0099656 (2003-05-01), Patti et al.
patent: 2004/0038327 (2004-02-01), Foster et al.
patent: 2004/0142348 (2004-07-01), Foster et al.
patent: 85/05553 (1985-12-01), None
patent: WO 93/09811 (1993-05-01), None
patent: WO 93/17044 (1993-09-01), None
patent: WO 94/06830 (1994-03-01), None
patent: 94/13310 (1994-06-01), None
patent: 94/18327 (1994-08-01), None
patent: WO 95/34655 (1995-12-01), None
patent: WO 97/43314 (1997-11-01), None
patent: WO 97/48727 (1997-12-01), None
patent: WO 98/31389 (1998-07-01), None
patent: WO 98/38312 (1998-09-01), None
patent: WO 99/27109 (1999-06-01), None
patent: WO 00/12131 (2000-03-01), None
Annaix, V et al, FEMS microbiology immunology, Oct. 1990, vol. 2(3), pp. 147-153, Structures involved in teh binding of humn fibrinogen to Candida albicans germ tubes (abstract only).
Nagata, H et al, Journal of Osaka University Dental School, Dec. 1994, vol. 34, pp. 37-44, Characterization of coaggregation and fibrinogen binding by Porphyromonas gingivalis. (abstract only).
Fischer, G, Pediatric Clinics of North America, vol. 35(3), Jun. 1988, pp 517-533, Therapeutic uses of intravenous gammaglobulin for Pediatric Infections.
Wadstrom, ACTA Microbiologica Hungarica, vol. 38, 1991, Microbial Adhesion: New concepts for development, pp 164-165.
Nilsson et al, J. Clin. Invest., Vaccination with a recombinant fragment of collagen adhesin provides protection againstStaphylococcus aureusmediated septic death.
Boden et al, Infection and Immunity, vol. 57(8), pp. 2358-2363, Aug. 1989.
Harris, LG et al, European Cells and Material, vol. 4, 2002, pp. 39-60.
Nilsson, M et al, Infection and Immunity, vol. 66(6), pges 2666-2673, Jun. 1998, A Fibriogen binding protein ofStaphylococcus epidermidis.
Christensen, GD et al, Infection and Immunity, vol. 40(1), pp. 407-410, Apr. 1983.
Neonatal Infectious Diseases, Program Issue APS-SPR, Washington DC, May 1-4, 1989, vol. 25, No. 4, Part 2.
Agarwal, “Subcutaneous Staphylococcal Infection in Mice . . . ”, Br. J. Exp. Pathology, Oct. 1967, vol. 48(5), p. 483-500.
Fischer, “Therapeutic Uses of Intravenous Gammaglobulin for Pediatric Infections”, Pediatric Clinics of North America, vol. 35, No. 3, Jun. 1988, pp. 517-533.
McDevitt et al., “Identification of the ligand-binding domain of the surface-located . . . ” Molecular Microbiology (1995), 16(5), pp. 895-907.
Murazyan et al., “Staphyloccal Infections and Their Treatment In Burned Patients”, ACTA Chirurgiae Plasticae 24, 3, 1982, pp. 180-184.
Fattom et al., “AStaphylococcus aureusCapsular Polysaccharide (CP) Vaccine and CP-Specific . . . ”, Infection and Immunity, May 1996, vol. 1996, vol. 64, No. 5, pp. 1659-1665.
Nilsson et al., “Vaccination with a Recombinant Fragment of Collagen Adhesin Provides Protection . . . ”, J. Clin. Invest., vol. 101, No. 12, Jun. 1998, pp. 2640-2649.
Patti et al., “Identification and Biochemical Characterization of the Ligand Binding Domain . . . ”, Biochemistry 1993, 32, pp. 11428-11435.
Yoshida et al., “Induction of Resistance with Heat-Killed Compact-type Strains ofStaphylococcus aureus. . . ” Infection and Immunity, Nov. 1975, vol. 12, No. 5, pp. 939-942.
Wadstrom, “Microbial adhesion: new concepts for development . . . ”, Acta Microbiologica Hungarica 38, 1991, pp. 164-165.
Takeda et al., “Protection Against Endocarditis Due toStaphylococcus epidermidis. . . ”, Circulation, vol. 84, No. 6, Dec. 1991, pp. 2539-2546.
Smeltzer et al., “Prevalence and chromosomal map location . . . ”, Gene 196 (1997), pp. 249-259.
Martinez et al., “Heterogeneous Surface Distribution of the Fibrinogen-Binding Protein . . . ”, Infection and Immunity, Feb. 1994, vol. 62, No. 2, pp. 709-712.
Espersen et al., “Immunization of Mice with the Fibronectin-Binding Protein . . . ”, Acta path. microbiol. immunol. scand. Sect. C, 93: 53-58, 1985.
Nilsson et al., “Vaccination with a Recombinant Fragment of Collagen Adhesin Provides . . . ”, J. Clin. Invest., vol. 101, No. 12, Jun. 1998, pp. 2640-2649.
McDevitt et al., “Variation in the size of the repeat region of the fibrinogen receptor”, Microbiology, 1995, 141, 937-943.
McCrea et al., “The serine-aspartate repeat (Sdr) protein family . . . ”, Microbiology (2000), 146, pp. 1535-1546.
Hartford et al., “The dipeptide repeat region of the fibrinogen-binding protein (clumping factor) is required . . . ”, Molecular Microbiology (1997), 25(6), pp. 1065-1076.
Foster et al., “Surface-associated proteins ofStaphylococcus aureus: Their possible roles in virulence”, FEMS Microbiology Letters 118 (1994), pp. 199-206.
Foster Timothy J.
Hook Magnus
Patti Joseph M.
Inhibitex, Inc.
Portner Ginny Allen
Schulman B. Aaron
Smith Lynette R. F.
LandOfFree
Staphylococcal immunotherapeutics via donor selection and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Staphylococcal immunotherapeutics via donor selection and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Staphylococcal immunotherapeutics via donor selection and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3623014